Cibc World Markets Corp Has $116.18 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Cibc World Markets Corp cut its stake in Johnson & Johnson (NYSE:JNJ) by 8.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 803,360 shares of the company’s stock after selling 70,054 shares during the period. Johnson & Johnson comprises approximately 0.7% of Cibc World Markets Corp’s holdings, making the stock its 26th largest holding. Cibc World Markets Corp’s holdings in Johnson & Johnson were worth $116,182,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Arbor Capital Management Inc. ADV increased its holdings in Johnson & Johnson by 4.5% during the 4th quarter. Arbor Capital Management Inc. ADV now owns 11,382 shares of the company’s stock valued at $1,722,000 after purchasing an additional 494 shares in the last quarter. Gold Investment Management Ltd. boosted its position in Johnson & Johnson by 1.0% in the 4th quarter. Gold Investment Management Ltd. now owns 17,389 shares of the company’s stock valued at $2,515,000 after buying an additional 168 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its position in Johnson & Johnson by 7.6% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company’s stock valued at $1,375,000 after buying an additional 668 shares during the last quarter. IMG Wealth Management Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at $483,000. Finally, Signature Wealth Management Group boosted its position in Johnson & Johnson by 4.9% in the 4th quarter. Signature Wealth Management Group now owns 27,864 shares of the company’s stock valued at $4,030,000 after buying an additional 1,295 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

JNJ opened at $162.94 on Monday. The business’s 50-day moving average price is $154.98 and its two-hundred day moving average price is $156.27. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market capitalization of $392.29 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.